Literature DB >> 29184697

Clinical presentation, diagnosis, classification and management of peritoneal mesothelioma: a review.

Alfonso García-Fadrique1, Akash Mehta2, Faheez Mohamed2, Sanjeev Dayal2, Tom Cecil2, Brendan J Moran2.   

Abstract

Peritoneal mesothelioma (PM) is an uncommon but a serious, and often, fatal primary peritoneal tumour, with increasing incidence worldwide. Conventional systemic chemotherapy, generally based on experience with pleural mesothelioma, usually has disappointing results considering PM as a terminal condition. Patients usually present with non-specific symptoms of abdominal distension and pain making the diagnosis challenging. As PM is confined to the abdomen for all, or much, of its clinical course, a multimodality treatment combining cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) has emerged as a new standard of care, and has been reported to achieve promising survival outcomes and local disease control in selected patients with PM. This review updates the presentation, diagnosis, classification and treatment strategies for PM.

Entities:  

Keywords:  Peritoneal mesothelioma (PM); cytoreductive surgery (CRS); hyperthermic intraperitoneal chemotherapy (HIPEC); peritoneal malignancy

Year:  2017        PMID: 29184697      PMCID: PMC5674249          DOI: 10.21037/jgo.2017.08.01

Source DB:  PubMed          Journal:  J Gastrointest Oncol        ISSN: 2078-6891


  68 in total

Review 1.  The epidemiology of mesothelioma in historical context.

Authors:  J C McDonald; A D McDonald
Journal:  Eur Respir J       Date:  1996-09       Impact factor: 16.671

Review 2.  Patient selection for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy, and role of laparoscopy in diagnosis, staging, and treatment.

Authors:  Mario Valle; Orietta Federici; Alfredo Garofalo
Journal:  Surg Oncol Clin N Am       Date:  2012-10       Impact factor: 3.495

3.  18F-FDG PET/CT in a recurrent diffuse malignant peritoneal mesothelioma.

Authors:  Qi Cao; Minh Lu; Jonathon Heath; Petr F Hausner; H Richard Alexander; Vasken Dilsizian; Wengen Chen
Journal:  Clin Nucl Med       Date:  2012-05       Impact factor: 7.794

4.  Malignant peritoneal mesothelioma: prognostic factors and oncologic outcome analysis.

Authors:  Deepa Magge; Mazen S Zenati; Frances Austin; Arun Mavanur; Magesh Sathaiah; Lekshmi Ramalingam; Heather Jones; Amer H Zureikat; Matthew Holtzman; Steven Ahrendt; James Pingpank; Herbert J Zeh; David L Bartlett; Haroon A Choudry
Journal:  Ann Surg Oncol       Date:  2013-12-10       Impact factor: 5.344

5.  The role of perioperative systemic chemotherapy in diffuse malignant peritoneal mesothelioma patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

Authors:  Marcello Deraco; Dario Baratti; Ionut Hutanu; Rossella Bertuli; Shigeki Kusamura
Journal:  Ann Surg Oncol       Date:  2013-03-02       Impact factor: 5.344

Review 6.  Clinical impacts of mesothelin expression in gastrointestinal carcinomas.

Authors:  Takahiro Einama; Futoshi Kawamata; Hirofumi Kamachi; Hiroshi Nishihara; Shigenori Homma; Fumihiko Matsuzawa; Tatsuzo Mizukami; Yuji Konishi; Munenori Tahara; Toshiya Kamiyama; Okio Hino; Akinobu Taketomi; Satoru Todo
Journal:  World J Gastrointest Pathophysiol       Date:  2016-05-15

7.  Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy.

Authors:  Andrew L Feldman; Steven K Libutti; James F Pingpank; David L Bartlett; Tatiana H Beresnev; Sharon M Mavroukakis; Seth M Steinberg; David J Liewehr; David E Kleiner; H Richard Alexander
Journal:  J Clin Oncol       Date:  2003-12-15       Impact factor: 44.544

8.  [Metastasis revealing malignant peritoneum mesothelioma: About the difficulty to identify the primary tumors].

Authors:  Charles-Henri Bretagne; Alain Petitjean; Sophie Felix; Isabelle Bedgedjian; Marie-Paule Algros; Eric Delabrousse; Séverine Valmary-Degano
Journal:  Ann Pathol       Date:  2016-03-16       Impact factor: 0.407

Review 9.  Advances in the systemic therapy of malignant pleural mesothelioma.

Authors:  Dean A Fennell; Giovanni Gaudino; Kenneth J O'Byrne; Luciano Mutti; Jan van Meerbeeck
Journal:  Nat Clin Pract Oncol       Date:  2008-03

10.  Laparoscopic hyperthermic intraperitoneal chemotherapy (HIPEC) for the treatment of malignant ascites secondary to unresectable peritoneal carcinomatosis from advanced gastric cancer.

Authors:  E Facchiano; S Scaringi; R Kianmanesh; J M Sabate; B Castel; Y Flamant; B Coffin; S Msika
Journal:  Eur J Surg Oncol       Date:  2007-07-20       Impact factor: 4.424

View more
  15 in total

1.  Localized gastric mesothelioma with nodal metastasis-an exceptionally rare entity.

Authors:  Mufaddal Kazi; Tejas Vispute; Prarthna Shah; Mukta Ramadwar; Manish S Bhandare; Shailesh V Shrikhande; Vikram A Chaudhari
Journal:  Indian J Surg Oncol       Date:  2022-04-03

Review 2.  Malignant peritoneal mesothelioma: a review.

Authors:  Glenn Broeckx; Patrick Pauwels
Journal:  Transl Lung Cancer Res       Date:  2018-10

3.  Establishment and characterization of a new malignant peritoneal mesothelioma cell line, KOG-1, from the ascitic fluid of a patient with pemetrexed chemotherapy resistance.

Authors:  Tomoko Akahane; Akira Hirasawa; Issei Imoto; Aki Okubo; Manabu Itoh; Yoshiko Nanki; Tomoko Yoshihama; Eichiro Tominaga; Daisuke Aoki
Journal:  Hum Cell       Date:  2019-10-03       Impact factor: 4.174

Review 4.  CT imaging review of uncommon peritoneal-based neoplasms: beyond carcinomatosis.

Authors:  Perry J Pickhardt; Alberto A Perez; Mohab M Elmohr; Khaled M Elsayes
Journal:  Br J Radiol       Date:  2021-01-05       Impact factor: 3.039

5.  Pediatric Mesothelioma With ALK Fusions: A Molecular and Pathologic Study of 5 Cases.

Authors:  Pedram Argani; Derrick W Q Lian; Abbas Agaimy; Markus Metzler; Sara E Wobker; Andres Matoso; Jonathan I Epstein; Yun-Shao Sung; Lei Zhang; Cristina R Antonescu
Journal:  Am J Surg Pathol       Date:  2021-05-01       Impact factor: 6.298

6.  The importance of primary tumor origin in gastrointestinal malignancies undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

Authors:  Natasha Leigh; Daniel Solomon; Eric Pletcher; Daniel M Labow; Deepa R Magge; Umut Sarpel; Benjamin J Golas
Journal:  World J Surg Oncol       Date:  2020-07-23       Impact factor: 2.754

7.  Is cytoreductive surgery and hyperthermic intraperitoneal chemotherapy indicated in hepatobiliary malignancies?

Authors:  Natasha Leigh; Daniel Solomon; Eric Pletcher; Daniel M Labow; Deepa R Magge; Umut Sarpel; Benjamin J Golas
Journal:  World J Surg Oncol       Date:  2020-06-11       Impact factor: 2.754

8.  Peritoneal mesothelioma in Sweden: A population-based study.

Authors:  Peter H Cashin; Gabriella Jansson Palmer; Dan Asplund; Wilhelm Graf; Ingvar Syk
Journal:  Cancer Med       Date:  2019-09-04       Impact factor: 4.452

9.  Splicing modulation as novel therapeutic strategy against diffuse malignant peritoneal mesothelioma.

Authors:  Rocco Sciarrillo; Anna Wojtuszkiewicz; Btissame El Hassouni; Niccola Funel; Paolo Gandellini; Tonny Lagerweij; Silvia Buonamici; Maxime Blijlevens; Eveline A Zeeuw van der Laan; Nadia Zaffaroni; Marcello Deraco; Shigeki Kusamura; Tom Würdinger; Godefridus J Peters; Carla F M Molthoff; Gerrit Jansen; Gertjan J L Kaspers; Jacqueline Cloos; Elisa Giovannetti
Journal:  EBioMedicine       Date:  2018-12-20       Impact factor: 8.143

10.  Evaluation of prognostic histological parameters proposed for pleural mesothelioma in diffuse malignant peritoneal mesothelioma. A short report.

Authors:  Federica Pezzuto; Luigi Vimercati; Francesco Fortarezza; Andrea Marzullo; Antonio Pennella; Domenica Cavone; Alessandra Punzi; Concetta Caporusso; Antonio d'Amati; Teresa Lettini; Gabriella Serio
Journal:  Diagn Pathol       Date:  2021-07-22       Impact factor: 2.644

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.